E-Learning

Deals with Hims & Hers, LifeMD and Ro follow dismissal of a lawsuit that challenged the FDA's determination Wegovy is no longer in shortage.

Data backup provider Commvault (NASDAQ:CVLT) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 23.2% year on year to $275 million. Guidance for next quarter’s revenue was better than expected at $268 million at the midpoint, 1.8% above analysts’ estimates. Its non-GAAP profit of $1.03 per share was 11% above analysts’ consensus estimates.

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 10.4% year on year to $169.2 million. The company’s full-year revenue guidance of $707.5 million at the midpoint came in 1% above analysts’ estimates. Its non-GAAP profit of $0.39 per share was 11.4% above analysts’ consensus estimates.

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 10.4% year on year to $169.2 million. The company’s full-year revenue guidance of $707.5 million at the midpoint came in 1% above analysts’ estimates. Its non-GAAP profit of $0.39 per share was 11.4% above analysts’ consensus estimates.

Hardware products and merchandising solutions provider Hillman (NASDAQ:HLMN) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 2.6% year on year to $359.3 million. On the other hand, the company’s full-year revenue guidance of $1.54 billion at the midpoint came in 0.5% above analysts’ estimates. Its non-GAAP profit of $0.10 per share was in line with analysts’ consensus estimates.

Hardware products and merchandising solutions provider Hillman (NASDAQ:HLMN) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 2.6% year on year to $359.3 million. On the other hand, the company’s full-year revenue guidance of $1.54 billion at the midpoint came in 0.5% above analysts’ estimates. Its non-GAAP profit of $0.10 per share was in line with analysts’ consensus estimates.

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 7.5% year on year to $168 million. On the other hand, the company’s full-year revenue guidance of $753 million at the midpoint came in 2% above analysts’ estimates. Its non-GAAP loss of $0 per share was in line with analysts’ consensus estimates.

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 7.5% year on year to $168 million. On the other hand, the company’s full-year revenue guidance of $753 million at the midpoint came in 2% above analysts’ estimates. Its non-GAAP loss of $0 per share was in line with analysts’ consensus estimates.

Packaged foods company Kraft Heinz (NASDAQ:KHC) met Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 6.4% year on year to $6.00 billion. Its non-GAAP profit of $0.62 per share was 2.7% above analysts’ consensus estimates.

Packaged foods company Kraft Heinz (NASDAQ:KHC) met Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 6.4% year on year to $6.00 billion. Its non-GAAP profit of $0.62 per share was 2.7% above analysts’ consensus estimates.